JY
Junsheng Yang
Lysoway Therapeutics, Inc., Zhejiang University of Technology, University of Southern California, Peking University, University of Michigan
0000-0002-6425-8495
About
I have been studying the protein quality control pathways in aging and age-related diseases in general. I am particularly interested in the aggregation and clearance of pathological proteins such as mutant huntingtin (mHTT) in cell models. The autophagy-lysosomal pathway, especially the lysosomal ion channel TRPML1 and transcription factor EB (TFEB), have been my main focus as potential pharmaceutical targets for clearing pathological protein aggregates.
Employment
-
Lysoway Therapeutics, Inc. Head of Discovery Research2020 - Present
-
Zhejiang University of Technology Assistant Professor2018 - 2023
-
Zhejiang University of Technology Post-doc2015 - 2018
-
University of Michigan Visiting Scholar2015 - 2016
-
Göteborgs Universitet Post-doc2009 - 2014
Education
-
University of Southern California Ph.D.2001 - 2008
-
Peking University B.S.1997 - 2001
Projects & Funding
Projects & funding information is unavailable.
Publications (26)
- Age‐ and disease‐related autophagy impairment in Huntington disease: New insights from direct neuronal reprogramming Save
- Targeting the autophagy-lysosomal pathway in Huntington disease: a pharmacological perspective Save
- A prion-like domain of TFEB mediates the co-aggregation of TFEB and mHTT Save
- SQSTM1/p62 droplet -mediated autophagosome formation:insights into Huntington disease Save
- Phase Transition of Huntingtin: Factors and Pathological Relevance. Save
- Rapamycin directly activates lysosomal mucolipin TRP channels independent of mTOR. Save
- Ion channels as potential redox sensors in lysosomes Save
- Release and uptake mechanisms of vesicular Ca2+ stores Save
- Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini-Review. Save
- Role of the ribosomal quality control machinery in nucleocytoplasmic translocation of polyQ-expanded huntingtin exon-1. Save